Brief: In8bio Observes Durable Morphologic Complete Responses In Ongoing Phase 1 Clinical Trial Of INB-100

IN8bio

27/07/2022 12:40

July 27 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO OBSERVES DURABLE MORPHOLOGIC COMPLETE RESPONSES IN
ONGOING PHASE 1 CLINICAL TRIAL OF INB-100, AN ALLOGENEIC
GAMMA-DELTA T CELL THERAPY IN HIGH-RISK LEUKEMIA PATIENTS
    * IN8BIO - ALL 3 PATIENTS FROM FIRST COHORT OF HIGH-RISK
RELAPSED
AML PATIENTS DOSED TO-DATE WITH INB-100 REMAIN ALIVE &
PROGRESSION-FREE AFTER AT LEAST 1 YEAR
    * IN8BIO - PATIENTS REMAIN IN MORPHOLOGICAL COMPLETE
REMISSION
WITH TWO PATIENTS OVER TWO YEARS AND A THIRD OVER ONE YEAR
POST-TRANSPLANT, RESPECTIVELY
    * IN8BIO, INC. - SAFETY PROFILE CONTINUES TO BE MANAGEABLE

Source text for Eikon:  ID:nGNX7q3j7V 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))